Consistently, pre- and post-treatment circulating tumor DNA analysis revealed increased c-Myc amplification in patients treated with abemaciclib compared with those treated with placebo, suggesting that c-Myc amplification may serve as a potential resistance mechanism89. Here, MYC is linked to neoplasm.